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Prescription Drug Overdose 
Definition
□  Type of poisoning
□  Prescription drugs used
in amounts or in ways NOT 
recommended
□  No harm intended by user
□  Limited number of ingestions 
by young children or innocent 
mistakes by patients
Prescription Drugs Overdose 
Type of Drugs and Reasons for Use
□  Types of drugs
> Drugs that depress breathing
■ Opioid analgesics
■ Sedative/hypnotics
> Usually multiple drugs involved
> Frequently combined with illicit drugs
□  Reason for use
> Original use of drug might have been their intended purpose: 
relief of pain or anxiety
> Development of tolerance
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National Vital Statistics System. http://wonder.cdc.gov
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27,658 unintentional drug overdose deaths: 
1 death every 19 minutes
Cocaine
Heroin
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Unintentional Overdose Deaths 
Involving Opioid Analgesics, Cocaine, and Heroin
United States, 1999-2007
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National Vital Statistics System. http://wonder.cdc.gov, multiple cause dataset
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Unintentional Overdose Deaths 
Involving Opioid Analgesics Parallel Opioid Sales 
United States, 1997-2007
□  Distribution by drug 
companies
> 96 mg/person in 1997
> 698 mg/person in 2007
■ Enough for every American 
to take 5 mg Vicodin 
every 4 hrs for 3 weeks
□  Overdose deaths
> 2,901 in 1999
> 11,499 in 2007
Year
Year
National Vital Statistics System, multiple cause o f death data set and Drug Enforcement Adm inistration ARCOS System >
* 2007 opioid sales figure is prelim inary
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Public Health Impact of Opioid Analgesic Use
For every 1 overdose death there are
Abuse treatment admissions 9






Treatm ent adm issions are for primary use o f opioids from  Treatm ent Exposure Data set /
Emergency departm ent (ED) visits are from  DAWN, Drug Abuse W arning Network, https://dawninfo.samhsa.gov/default.a: 
Abuse/dependence and nonmedical use in the past month are from  the National Survey on Drug Use and Health . — [
Far-reaching Public Health Impact 
of Widespread Opioid Analgesic Use
□ Mental impairment leads to other types of unintentional injuries
> Falls and fractures among elderly
> Motor vehicle crashes involving “drugged driving”
□ Substance abuse leads to intentional injuries
> Drug-related self harm and drug-crime-related interpersonal violence
□ Intravenous use of drugs leads to infections
> HIV transmission related to injection of dissolved tablets
> Hepatitis C: “Graduating” from oral OxyContin to injected heroin
□ Reproductive health effects
> Congenital defects associated with opioid exposure i n  u t e r o
> Newborn withdrawal syndrome
> Infertility from chronic heavy use
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High-risk Groi 
Opioid Abuse and Ov<
□  Men for overdose deaths
□  Ages 2 0 - 6 4  for deaths and 
emergency department visits
□  Whites
□  Medicaid populations
□  Rural populations
□  Mentally ill, especially people 
with depression
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N ationa l V ita l S ta tis tics  S ystem , Drug A buse  W arn ing  N etw ork. h ttps://daw nir 






Opioid Analgesics: Users in the Past Month
N a t io n a l S u rv e y  o n  D ru g  U s e  a n d  H e a lth ,  2 0 0 9 . h t tp : / /w w w .o a s .s a m h s a .g o v
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d Prescribed to 
someone else
□ Prescribed to user
u Other
N a t io n a l S u rv e y  o n  D ru g  U s e  a n d  H e a lth .  S u m m a r y  o f  n a t io n a l f in d in g s ,  2 0 0 8 -2 0 0 9  
h t tp : / /w w w .o a s .s a m h s a .g o v
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Nonmedical Users 
Among People Dying of Opioid Overdoses





West Virginia, 2006 66
Utah, 2008-2009 37
Ohio, 2006-2008 25
W e s t  V irg in ia :  H a ll A J ,  e t  a ll. J A M A  2 0 0 8 ;3 0 0 :2 6 1 3 -2 0
O h io :  O h io  D e p a r tm e n t  o f  H e a lth .  w w w .h e a lth y o h io p r o g ra m .o r g /d is e a s e p r e v e n t io n /d p o is o n /d r u g d a ta .a s p x  
U ta h : L a n ie r  W . 2 0 1 0 . C D C  E p id e m ic  In te l l ig e n c e  S e rv ic e  C o n fe re n c e
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History of Seeing Multiple Prescribers 
among People Dying of Opioid Overdoses
Definition % deaths
>5 prescribers per year 
West Virginia, 2006 21
Average of 5 prescribers per year 
over 3 years 
Ohio, 2006-2008
16
W e s t  V irg in ia :  H a ll A J ,  e t  a ll. J A M A  2 0 0 8 ;3 0 0 :2 6 1 3 -2 0







Risk of Overdose by Prescribed Opioid Dosage 


















Distributions of Opioid Usage and Overdoses 





















> 1 0 0
D u n n  K M , e t  a l. A n n  In t M e d  2 0 1 0 ;1 5 2 :8 5 -9 2
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Distribution of Patients and Overdoses 
by Risk Group
Patients Overdoses
« Patients involved in 
drug diversion
 ̂ Patients seeing one 
doctor, high dose
Patients seeing one 
doctor, low dose
□  Improve usage and effectiveness of 
prescription drug monitoring programs
□  Use insurance mechanisms to
> Prevent doctor shopping
> Reduce inappropriate use of opioids
□  Improve state legislation
S T R A T E G I E S
S t r a t e g i e s  T a r g e t i n g  H i g h - r i s k  G r o u p s
M o n i t o r i n g  a n d  I n s u r a n c e
□  Improve effectiveness of prescription drug 
monitoring programs
> Track the rate of use of multiple providers and high dosage,
□  Restrict selected patients to one provider and one 
pharmacy (by Medicaid and others insurers)
□  Insurers can restrict payment for inappropriate use, 
e.g., use of long-acting opioids for short-term pain
S t r a t e g i e s  T a r g e t i n g  H i g h - r i s k  G r o u p s :
I m p r o v i n g  L e g i s l a t i o n  a n d  E n f o r c e m e n t
□  Improve legislation and enforcement of existing laws 
including
> Doctor shopping: Laws exist in 33 states
> Reduce “pill mills” and other fraud through
■ Licensure and inspection laws: 3 states
■ Requirements for physical exams before prescribing: 32 states
■ Stopping drug distribution to “pill mills”
> Dispensing practice: ID requirement at dispensing: 11 states
STRATEGIES
S t r a t e g i e s  T a r g e t i n g  H i g h - r i s k  G r o u p s
I m p r o v i n g  P h y s i c i a n  P r a c t i c e
□  Develop physician guidelines
> Especially in emergency departments
> With accountability
□  Improve physician competence for safe prescribing 
of methadone
□  Use single copy, serialized, tamper-resistant paper 
prescription forms or E-prescribing
_ 1 0 % 2 0 1 8 % S b 0 7 _ B r ie f% 2 0 w % 2 0 a t tc h .p d f
STRATEGIES
Strategies Targeting High-risk Groups 
Secondary and Tertiary Prevention
□  Expand use of overdose harm reduction programs
> Including more widespread distribution of the opioid antidote, 
naloxone
□  Expand use of buprenorphine for treatment of opioid 
dependence
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C h a n g e  i n  N a t i o n a l  N o r m s  f o r  U s e  o f  O p i o i d s
f o r  C h r o n i c ,  N o n - c a n c e r  P a i n
□  By the late 1990s, at least 20 states 
passed new laws, regulations, or 
policies moving from near prohibition 
of opioids to use without dosing 
guidance
> WA law: “No disciplinary action will be taken 
against a practitioner based solely on the 
quantity and/or frequency of opioids 
prescribed.” (WAC 246-919-830, 12/1999)
□  Laws were based on weak science and 
good experience with cancer pain



























Average Daily Dosage of Long-acting Opioids 
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M E D , M o rp h in e  e q u iv a le n t  d o s e
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Limitations of Long-term (>3 Months) 
Opioid Therapy




B a lla n ty n e  J . P a in  P h y s ic ia n  2 0 0 7 ;1 0 :4 7 9 -9 1
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Putative mechanisms for failed opioid analgesia may 
be related to rampant tolerance
The premise that tolerance can always be overcome 
by dose escalation is now questioned
□  100% of patients on opioids chronically develop 
dependence
C h r o n i c  O p i o i d  U s e  a m o n g  W o r k e r s  w i t h
B a c k  I n j u r i e s ,  W a s h i n g t o n  S t a t e ,  2 0 0 2 - 2 0 0 5
□  Prospective study of 1,843 injured workers with 
back pain
□  37.6% received an opioid early, most on first visit
□  6.0% received opioids for 1 year
> Daily dose increased significantly from 1st -  4th quarters after injury
□  Clinically significant improvement was limited to a 
fraction of patients
> 26% patients improved in pain and 16% improved in function
Strategies in Washington State 
to Address Opioid Overdosing
□  Provide Opioid Dosing Guidance for primary care 
providers
□  Strengthen the legislation
□  Improve physician access to pain management 
specialists
□  Offer community-based treatment of chronic pain
S T R A T E G I E S
Washington Agency Medical Directors 
Opioid Dosing Guidelines
□  Developed with clinical pain experts in 2006
□  Implemented April 1, 2007
□  First guideline to emphasize dosing guidance
□  Educational pilot, not new standard or rule
□  National Guideline Clearinghouse
> http://www.guideline.gov/content.aspx?id=23792&search=wa+opioids
Interagency Guideline 
on Opioid Dosing for 
Chronic Non-cancer Pain:
A n  e d u c a t i o n a l  a i d  t o  i m p r o v e  
c a r e  a n d  s a f e t y  w i t h  o p i o i d  t h e r a p y
2010 Update
Washington Agency Medical Directors 
Opioid Dosing Guidelines
□  Part I -  If patient has not had clear improvement in 
pain AND function at 120 mg MED (morphine 
equivalent dose) “take a deep breath”
> If needed, get one-time pain management consultation 
(certified in pain, neurology, or psychiatry)
□  Part II -  Guidance for patients already on very high 
doses >120 mg MED
The main emphasis was on preventing 
future cohorts of high-dose patients
Guidance for Primary Care Providers on Safe and 
Effective Use of Opioids for Chronic Non-cancer Pain
□  Establish an opioid treatment agreement
□  Screen for
> Prior or current substance abuse
> Depression
□  Use random urine drug screening judiciously
> Shows patient is taking prescribed drugs
> Identifies non-prescribed drugs
□  Do not use concomitant sedative-hypnotics
□  Track pain and function to recognize tolerance
□  Seek help if dose reaches 120 mg MED, and pain and 
function have not substantially improved
h t tp : / /w w w .a g e n c y m e d d ire c to r s .w a .g o v /o p io id d o s in g .a s p  
M E D , M o rp h in e  e q u iv a le n t  d o s e
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Washington State Primary Care Survey 2009 
Physician Concerns
Please check the statement that most accurately reflects 
your experience when prescribing opioids 
for chronic, non-cancer pain
NO concerns about development of psychological 
dependence, addiction, or diversion 2%
OCCASIONAL concerns about development of 
psychological dependence, addiction, or diversion 45%
FREQUENT concerns about development of 
psychological dependence, addiction, or diversion 54%
In te r im  E v a lu a t io n  o f  th e  O p io id  D o s in g  G u id e lin e s .  h t tp : / /w w w .a g e n c y m e d d ir e c to r s .w a .g o v
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Washington State Primary Care Survey 2009: 









Use treatment agreement 10% 22% 20% 49%
Screen for substance abuse <1% 3% 15% 81%
Screen for mental illness <1% 12% 30% 58%
Use random urine screen 30% 32% 18% 20%
Use patient education 34% 38% 19% 9%
Track pain 40% 31% 15% 15%
Track physical function 69% 20% 7% 5%
In te r im  E v a lu a t io n  o f  th e  O p io id  D o s in g  G u id e lin e s .  h t tp : / /w w w .a g e n c y m e d d ir e c to r s .w a .g o v
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O p e n - s o u r c e  T o o l s  A d d e d  t o  J u n e  2 0 1 0
U p d a t e  o f  O p i o i d  D o s i n g  G u i d e l i n e s
□  Opioid Risk Tool: Screen for past and current 
substance abuse
□  CAGE-AID screen for alcohol or drug abuse
□  Patient Health Questionnaire-9 screen for depression
□  2-question tool for tracking pain and function
□  Advice on urine drug testing
OPIO ID D O SE  CALCULATOR
Opioid (oral or transdermal)
codeine




up to 20mg per day 
21 to 40mg per day 
41 to 60mg per day 




TOTAL daily m orphine equivalent dose (MED)
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U n i n t e n t i o n a l  P r e s c r i p t i o n  O p i o i d  O v e r d o s e
D e a t h  a n d  H o s p i t a l i z a t i o n  R a t e s
W a s h i n g t o n  S t a t e ,  1 9 9 5 - 2 0 0 9
Year
* T r a m a d o l-o n ly  d e a th s  in c lu d e d  in  2 0 0 9 , b u t n o t in  p r io r  y e a rs .
W a s h in g to n  S ta te  D e p a r tm e n t  o f  H e a lth ,  D e a th  C e r t i f ic a te s  a n d  C o m p re h e n s iv e  A b s t r a c t  R e p o r t in g  S y s te m  (C H A R S )
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Washington State Legislation on 
Opioid Treatment in 2010
□  Repeals current regulation; new expected by June 2011
□  Provides specific dosing guidance and guidance 
on consultations, assessments, and tracking
□  Signed into law by Governor Gregoire on March 25, 2010
Washington State Opioid Treatment Regulations 
(DRAFT)
□  Emphasize tracking patients for improved 
pain AND function
□  Emphasize widely agreed-upon best practices
> Screening for substance abuse and other comorbidities
> Prudent use of urine drug screens
> Opioid treatment agreement
> Single pharmacy and single prescriber
□  Encourage use of Prescription Monitoring Program 
and Emergency Department Information Exchange, 
when available
Improving Physician Access to 
Pain Specialists in Washington State
□  Issue
> Moderate capacity problem: not enough pain specialists
> Interventional anesthesiologists generally will not see these 
patients to assist with opioid issues
□  Solution
> Advanced training for primary care to increase proficiency
> Have successfully “beta tested” telemedicine consults and 
webinar trainings with pain specialists and primary care 
physicians
> Telephonic or video consultation with experts
> Public payers working on payment codes to incentivize 
these activities
C o m p o n e n t s  B e i n g  D e v e l o p e d  f o r
C o m m u n i t y - b a s e d  T r e a t m e n t  o f  C h r o n i c  P a i n
□  Cognitive behavioral therapy
□  Graded exercise
□  Activity coaching
□  Interdisciplinary care
□  Care coordination
Lessons Learned from Washington State
□  Opioid overdose is a public health crisis
□  High doses and rampant tolerance are key factors
□  A more comprehensive approach to effectively 
treating chronic pain must be developed
□  Statewide change through collaboration is needed
□  Prescriber education requires appropriate tools and 
dosing guidance
□  Prescriber education alone is not adequate
□  New state regulations are needed to ensure best 
practices and to prevent worst practices
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w w w . w h i t e h o u s e d r u g p o l i c y . g o v
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Overview
□  Authority and role of the White House
Office of National Drug Control Policy (ONDCP)
□  Federal policy perspective
□  Federal, state, local, and tribal coordination
ONDCP’s Authority
□  Established by the Anti-Drug Abuse Act of 1988
□  Principal purpose: Establish policies, priorities, and 
objectives for the nation's drug control program
□  Goals: Reduce illicit drug use, manufacturing, and 
trafficking, drug-related crime and violence, and 
drug-related health consequences
w w w . w h i t e h o u s e d r u g p o l i c y . g o v
50 4
ONDCP’s Role
□  Responsible for developing the N a t i o n a l  D r u g  
C o n t r o l  S t r a t e g y
□  Advise the President regarding Federal Drug Control 
Agencies’ activities
□  Coordinate/oversee international and domestic anti­
drug efforts of executive branch agencies
□  Establish a program, budget, and guidelines for 
cooperation among federal, state, and local entities
2010 National Drug Control Strategy
□  Science-based, public health approach to drug policy
□  Coordinated federal effort on 106 action items
Adoix i Sne mss Conag
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2 0 1 0  N a t io n a l  S tra teg y
The 2010 National Drug Control Strategy was developed by 
ONDCP with input from Federal, State, and local partners. It 
provides a collaborative and balanced approach that emphasizes 
community-based prevention, integration of evidence-based 
treatment into the healthcare system, innovations in the criminal 
justice system, and international partnerships to disrupt drug 
trafficking organizations.
Because nearly all Americans are impacted by the consequences 
of drug use, the Strategy is designed to be relevant at the local 
level. Whether you are a parent looking for information, a 
community member interested in treatment resources, a police 
officer or local elected official searching for new approaches to 
drug-related crimes, or someone who wants to know more about 
the Administration's drug policy, the National Drug Control 
Strategy will serve as a useful resource.
To the Congress Of the United States
I  am committed to restoring balance v? our efforts to combat the drug 
problems that plague our communities. Drug use endangers the health and 
safety of every American, depletes financial and human resources, and 
deade~s the spmt of many of our communities. IVJvJe 1 am proud of the nen 
direcbon descnbed here, a r/eti-crafted strategy is only as successful as its 
implementation To succeed, rre tv.'.1. need to rely on the hard rrork, 
dedication, and perseverance of every soncemed American
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Presdert Barack Obama meets with 
Director Natior-al Drug Control Policy Gil 
Kertikowske « the Oval OÎTiee. May 10. 
2010. (OfToal White House Photo by Pete 
Souu)
N A T I O N A L  D R U G  
C O N T R O L  S T R A T E G Y
2010
w w w . w h i t e h o u s e d r u g p o l i c y . g o v / s t r a t e g y
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2010 National Drug Control Strategy 
Signature Initiatives
□  Three signature initiatives
-«me asoj: 5 ■* Ms; CocG»a
O ffice o f  N a tiona l Drug C ontro l Policy
P o l ic y
R e co ve ry
M a rke t D is ru p t io n
D ru g  F a c ts
In te rn a t io n a l




O f  S u b s t a n c e  B l o g
P r e s id e n t 's  N a t io n a l  D ru g  C o n t r o l  B u d g e t :  C o n t in u in g  
I n c r e a s e d  S u p p o r t  f o r  P r e v e n t io n  a n d  T r e a t m e n t
T h e  F Y  2012 b u d g e t  r e q u e s t  in c lu d e s  fu n d in g  fo r  c r i t i c a l  
a r e a s  o f  d ru g  c o n t r o l  p o l i c y .  M o re
H u n d re d s  o f  Y o u n g  L e a d e r s  G e t  I n v o lv e d  w i t h  C o m m u n it y  
C o a l it io n s
M o r e  th a n  300 y o u n g  p e o p le  a t te n d e d  t h e  C o m m u n it y  
A n t i - D r u g  C o a l i t i o n s  o f  A m e r i c a  ( C A D C A )  N a t io n a l  
L e a d e r s h ip  F o ru m . M o r e
I n n o v a t io n s  in  t h e  C r im in a l  J u s t i c e  S y s t e m
T h e  O b a m a  A d m in i s t r a t io n  s e e k s  to  d e v e lo p  a fu ll 
c o n t in u u m  o f  e v id e n c e - b a s e d  a p p r o a c h e s  to  d ru g  c o n t r o l  
p o l i c y .  M o r e
Meda Center
MOW PLAYING: National Drug Facts Week
> Prescription drug abuse
> Prevention
> Drugged driving
w w w . w h i t e h o u s e d r u g p o l i c y . g o v
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Federal Policy Perspective
□  Policy must balance the desire to minimize abuse 
with the need to ensure legitimate access
□  Multifaceted approach and collaboration among 
federal, state, local, and tribal groups is key
□  Four focus areas
1. Education
2. Prescription drug monitoring programs
3. Proper medication disposal
4. Enforcement
1. Education
□  Education for parents and patients
> Increase awareness
> Safe medication use, storage, and disposal
□  Education for health care providers
> Appropriate prescribing
> Adverse events and drug interactions
> Identifying those at risk for abuse
> Counseling on proper storage and disposal
> Screening, intervention, and referral for those misusing or 
abusing prescription drugs
Distribution of Narcotic Analgesics to Patients 
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2 .  P r e s c r i p t i o n  D r u g  M o n i t o r i n g  P r o g r a m s
( P D M P s )
□  Tool to identify
> Inappropriate prescribing, dispensing, and drug-seeking behavior
> Drug interactions and therapeutic duplication
□  Goals
> All states have operational PDMPs
> Mechanisms in place for communication between states
> High utilization among health care providers
■ Regular part of office visit like checking insurance coverage
□  Positive data are starting to surface*
> More data on effectiveness and outcomes is needed
.atswicEj.
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3. Proper Medication Disposal
□  National Take Back Day
> September 2010: 121 tons of drugs 
were taken back at >4,000 sites 
across the country
> April 30, 2011: Next Take Back Day
□  Secure and Responsible Drug Disposal Act 2010
> Object: Allow ultimate users to give back controlled substances 
to an authorized entity
□  Drug Enforcement Administration rule-making underway
Got Drugs?
Turn in your  u n u sed  or expired  
m edication  for sa fe  d isp o sa l Saturday, S ep t. 25th
V is it  w w w .d ea .g ov  
fo r  a  c o lle c t io n  
s ite  n ea r you .
www.nationaltakebackday.com
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3. Proper Medication Disposal
□  Goals
> To be easily accessible and an 
environmentally friendly method of 
drug disposal
> To be cost-effective and not 
a burden on consumers
> To reduce the amount of 
prescription drugs available 
for diversion and abuse
Got Drugs?
Turn in your u n u sed  or expired  
m edication  for sa fe  d isp o sa l Saturday, S ep t. 25th
V is it  w w w .d ea .g ov  
fo r  a  c o lle c t io n  
s ite  n ea r you .
4. Enforcei
□  Assist states in addressing “ 
shopping
> Provide technical assistance to 
states on model regulations/laws 
for pain clinics
> Encourage high-intensity drug 
trafficking areas to work on 
prescription drug abuse issues
> Support prescription drug abuse- 




pill mills” and doctor
Federal, State, Local, and Tribal Coordination
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Drug Free Communities Program (DFC)
□  Support community coalitions in their efforts to 
reduce local substance use
> Reduce substance use among youth in the community
> Increase collaboration in the community regarding substance use
□  1,600 grantees since 1997
□  $85.6 million awarded to 746 DFCs in 2009
□  Planning process based on SAMHSA’s Strategic 
Prevention Framework
> Assessment, capacity, planning, implementation, and evaluation
□  56% of current grantees target prescription drug 
abuse in their communities
h t tp : / /w w w .o n d c p .g o v /d fc
h t tp : / /w w w . jo in to g e th e r .o rg / r e s o u r c e s /s a m h s a s - s t ra te g ic -p r e v e n t io n .h tm l 
S A M S H A , S u b s ta n c e  A b u s e  a n d  M e n ta l H e a lth  S e rv ic e s  A d m in is t ra t io n
62
Drug Free Communities
741 Drug Free Communities Program Grantees for Fiscal Year 2010
•  N ew  M e n to r in g  G ran tee  (16)
O  Con ti nua tio n  M e n to r in g  G ran te e  (7)
Puerto RicoJ American
US Virgin Islands Samoa Sourcei Drug-free Communities Program, ONDCP (August ÌOIO).
http://www.ondcp.gov/dfc
63
National Youth Anti-Drug Media Campaign
^VICES.
464
T E L L  U S  W H Y  Y O U 'R E
A B O V E  T H E  I N F L U E N C E
A N D  VO U  C O U L D  B E  O U R  W E*T  
F E A T U R E D  P R O F IL E .
www.abovetheinfluence.com
Why d o you think  
tEE-nE drink at parti«?
National Youth Anti-Drug Media Campaign
□  Combined national and local approach
> Engaging Local Communities: Aimed at getting teens to share 
insights about positive and negative influences in their 
communities and their approach to “staying above it”
□  Balances broad prevention messaging at the national 
level with targeted efforts at the local community level
□  “Self-reported exposure to the ONDCP campaign 
predicted reduced marijuana use”
S la te r  M D , e t  a l. A s s e s s in g  M e d ia  C a m p a ig n s  L in k in g  M a r i ju a n a  N o n -U s e  w ith  A u to n o m y  a n d  A s p ir a t io n s :  “ B e  
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□  Prescription drug abuse and its consequences are the 
fastest growing drug problem in America
□  Comprehensive four pillar approach addresses each 
aspect of the prescription drug abuse epidemic
□  Parents, peers, youth influencers, health care 
professionals, and policy-makers all have a role to play
□  Success will come from coordination and collaboration 
at the federal, state, local, and tribal level
